Genmab
$34.55Change from previous close: −3.15%Absolute change: −$1.13
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $21.56B
- Enterprise value
- $24.39B
- P/E (trailing 12 months)
- 27.2
- Forward P/E
- 21.7
- PEG
- 4.49
- Price/book
- 3.46
- Price/sales
- 5.22
- EV/EBITDA
- 17.7
- EV/revenue
- 5.90
Profitability and growth
- Gross margin
- 93.0%
- Operating margin
- 35.2%
- Net margin
- 19.1%
- ROE
- 14.0%
- ROA
- 8.8%
- Revenue growth (year over year)
- 24.9%
- Earnings growth (year over year)
- -9.4%
Financial health
- Total cash
- $1.51B
- Total debt
- $5.27B
- Debt/equity
- 0.89
- Current ratio
- 2.46
- Quick ratio
- 2.44
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $39.05
- Median price target
- $40.00
- High price target
- $45.00
- Low price target
- $32.00
- Analysts with a price target
- 10
- Consensus
- Strong buy
- Forward EPS
- $1.59
- EPS estimate, current year
- $1.18
Shares and trading
- Beta
- 0.70
- Average volume
- 2.41M
- Shares outstanding
- 624.06M
- Float
- 589.61M
- Institutional ownership
- 17.0%
- Insider ownership
- 0.0%
- Short interest (% of float)
- 0.8%
- Short ratio (days)
- 2.16